Genmab A/S (NASDAQ:GMAB) Given Consensus Rating of "Hold" by Brokerages

Genmab A/S (NASDAQ:GMAB - Get Free Report) has received a consensus recommendation of "Hold" from the thirteen ratings firms that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $48.50.

A number of research firms recently commented on GMAB. HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Thursday, April 4th. Citigroup lowered Genmab A/S from a "neutral" rating to a "sell" rating in a research report on Monday, January 22nd. Truist Financial reissued a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Tuesday, March 26th. BMO Capital Markets raised Genmab A/S from a "market perform" rating to an "outperform" rating and boosted their target price for the company from $46.00 to $48.00 in a research report on Friday, February 23rd. Finally, Morgan Stanley reissued an "underweight" rating on shares of Genmab A/S in a research report on Tuesday, March 26th.

Hedge Funds Weigh In On Genmab A/S

Several institutional investors and hedge funds have recently bought and sold shares of GMAB. Alliancebernstein L.P. boosted its position in shares of Genmab A/S by 21.0% during the 2nd quarter. Alliancebernstein L.P. now owns 8,187,576 shares of the company's stock valued at $311,210,000 after acquiring an additional 1,420,915 shares in the last quarter. BlackRock Inc. boosted its position in shares of Genmab A/S by 1.6% during the 1st quarter. BlackRock Inc. now owns 5,494,689 shares of the company's stock valued at $198,799,000 after acquiring an additional 86,571 shares in the last quarter. Capital International Investors boosted its position in shares of Genmab A/S by 7.7% during the 1st quarter. Capital International Investors now owns 3,952,446 shares of the company's stock valued at $145,433,000 after acquiring an additional 283,031 shares in the last quarter. Macquarie Group Ltd. boosted its position in shares of Genmab A/S by 11.1% during the 1st quarter. Macquarie Group Ltd. now owns 3,484,632 shares of the company's stock valued at $131,580,000 after acquiring an additional 347,437 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in shares of Genmab A/S by 5.8% during the 1st quarter. Wellington Management Group LLP now owns 3,333,824 shares of the company's stock valued at $120,618,000 after acquiring an additional 183,578 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Price Performance

NASDAQ GMAB traded down $0.48 during midday trading on Friday, hitting $29.26. 413,219 shares of the company traded hands, compared to its average volume of 390,206. The company has a market cap of $19.33 billion, a PE ratio of 30.48, a price-to-earnings-growth ratio of 2.10 and a beta of 0.99. The company's 50-day simple moving average is $29.27 and its 200-day simple moving average is $30.45. Genmab A/S has a 52 week low of $26.32 and a 52 week high of $42.99.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.02. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. The business had revenue of $675.29 million during the quarter, compared to analyst estimates of $678.14 million. On average, research analysts predict that Genmab A/S will post 1.06 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.